LV Dssynchrony and Cardiac Resynchronization Therapy in Heart Failure Nisha I. Parikh MD MPH August 13 th 2008.

Slides:



Advertisements
Similar presentations
Agenda Introduction Classes of recommendations Level of evidence
Advertisements

Prevalence and Predictors of Off-label Use of Cardiac Resynchronization Therapy: A Report from the ICD Registry TM Adam S. Fein * MD, Yongfei Wang ¥ MS,
Presenter Disclosure Information
Assessment of left ventricular function
Advance Heart Failure Therapy
EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.
Advanced Heart Failure and the Role of Mechanical Circulatory Support
Cardiac Resynchronization Therapy
CMR of Non-ischemic Dilated and Restrictive Cardiomyopathies
Airley E. Fish MD Imaging Conference August 19th 2009
Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled Trial Investigating.
Device Therapy in Heart Failure
Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
Dementia IGHC Tatiana Kuznetsova, Jan A. Staessen University of Leuven, Belgium Diagnostic criteria for subclinical systolic and diastolic LV function.
Natale MARRAZZO Francesco SOLIMENE Quando la CRT-P può bastare?
Echocardiographic Assessment of LV Systolic Function
Diminished Left Ventricular Dyssynchrony and Impact of Resynchronization in Failing Hearts With Right Versus Left Bundle Branch Block J Am Coll Cardiol.
Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Ventricular Diastolic Filling and Function
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Quantitative Assessment of Congestive.
Treatment of Heart Failure: Beyond Medical Therapy
Current Management of Heart Failure GP clinical update 17 th June 2015 Dr Raj Bilku Consultant Cardiologist Clinical Lead Cardiology QEH.
La selezione dei pazienti candidati alla Terapia Resincronizzante Cardiaca M Cristina Porciani Firenze “Incontri Pitagorici di Cardiologia 2010” “Πυθαγόρειοι.
TISSUE DOPPLER BASICS DR BIJILESH U.
Working Group of Heart Failure and Cardiac Function How to evaluate and treat dyssynchrony ? P Lancellotti, LA Piérard, Liège, BE.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:
Target Study Cardiac resynchronization therapy (CRT) is an established treatment for advanced heart failure symptoms, impaired LV systolic function, and.
Results of the Predictors of Response to CRT (PROSPECT) Trial Chung ES, Leon AR, Tavazzi L, Sun J-P, Nihoyannopoulos P, Merlino J, Abraham WT, Ghio S,
Cardiac Resynchronization Therapy (CRT) Is an Effective Treatment for Heart Failure and Indications Are Expanding Multiple trials have shown the clinical.
S. HUNT Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
1 ASSESSMENT OF LEFT VENTRICULAR SYSTOLIC DYSFUNCTION BY TISSUE DOPPLER IMAGING SHOWS EVIDENCE OF SUBCLINICAL CARDIOMYOPATHY EARLY AFTER ATHRACYCLINE THERAPY.
SMMART-HF Surgery vs. Medical Treatment Alone for Patients with Significant MitrAl RegurgitaTion & Non-Ischemic Congestive Heart Failure Duke Heart Failure.
Acute effects of RV pacing on cardiac hemodynamics and transvalvular impedance M.Taborsky, M.Fedorco, T.Skala, E.Kocianova, D.Richter, D.Marek, J.Ostransky.
Dr Eric Prystowsky Director Clinical Electrophysiology Laboratory St Vincent Hospital, Indianapolis Dr Leslie Saxon Chief, Electrophysiology Laboratory.
Nonischemic regional wall motion abnormality - LBBB
Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with preserved Ejection Fraction Effect of Spironolactone.
CRT Overview This lecture is intended to give a basic overview of HF to include: -General knowledge of the cardiac cycle and how a normal heart should.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Influence of Left Ventricular Ejection Fraction.
RCTs in Cardiac Resynchronization Therapy StudyPtNYHALVEFLVEDDRhythmQRSICD PATH-CHF41III,IV≤35%AnySR≥120N MUSTIC58III≤35%≥60SR≥150N MIRACLE453III,IV≤35%≥55SR≥130N.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiopoietic Stem Cell Therapy in Heart Failure:
Left Ventricular Pacing in the Early Post MI Period: Impact on LV Remodeling Eugene S.Chung, MD Director, Heart Failure Program, Director of Outcomes,
Date of download: 11/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Targeted Left Ventricular Lead Placement to Guide.
Total Occlusion Study of Canada (TOSCA-2) Trial
Diminished Left Ventricular Dyssynchrony and Impact of Resynchronization in Failing Hearts With Right Versus Left Bundle Branch Block J Am Coll Cardiol.
– р<0.05 between baseline
Ventricular Pacing Alters Twisting Synchrony of the Left Ventricle
ISCHEMIC CASCADE.
Επιλογή ασθενών για θεραπεία καρδιακού επανασυγχρονισμού με εκτίμηση δυσυγχρονισμού και τη χρήση δυναμικής ηχωκαρδιογραφίας με δοβουταμίνη. Ε. Πουλιδάκης1,
Kuznetsov VA, Soldatova AM, Krinochkin DV, Enina TN
Volume 9, Issue 1, Pages (January 2012)
O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.
2) Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114
Optimal Pacing for Right Ventricular and Biventricular Devices
The American Heart Association
Left Ventricular and Biventricular Pacing in Congestive Heart Failure
Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection  Derek V. Exner, MD, MPH, David.
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
Study Design Patients with LBBB and LV dysfunction
Volume 9, Issue 8, Pages S3-S13 (August 2012)
Gaurav A. Upadhyay, MD, Jonathan S. Steinberg, MD  Heart Rhythm 
Division of Cardiovascular Diseases No relevant author disclosures
Echocardiographic Assessment of Left Ventricular Systolic Function: An Overview of Contemporary Techniques, Including Speckle-Tracking Echocardiography 
Volume 14, Issue 12, Pages (December 2017)
Understanding the cardiac substrate and the underlying physiology: Implications for individualized treatment algorithm  John Gorcsan, MD, Frits W. Prinzen,
Tasneem Z. Naqvi JIMG 2010;3: Effect of Sequential Ventricular Pacing on Mechanical Asynchrony Tissue synchronization images are shown in the.
Presentation transcript:

LV Dssynchrony and Cardiac Resynchronization Therapy in Heart Failure Nisha I. Parikh MD MPH August 13 th 2008

Summary of Talk Background CRT Rational and Evidence for Benefit LV Dssynchrony by Echocardiography Evidence for Ability of Echo to Predict CRT Response

Hospital discharges for HF from American Heart Association. Heart Disease and Stroke Statistics — 2007 Update 1,099,000

HF Total Expenditures: $27.9 Billion American Heart Association. Heart Disease and Stroke Statistics — 2007 Update

Percent Change in United States Crude Death Rates from 1972 to 2000 by cause NHLBI Morbidity and Mortality Chart Book. 2004

HF Therapy Jessup M, Brozena S. Medical Progress--Heart Failure. N Eng J Med 2003; 348: Copyright 2002 Massachusetts Medical Society. All rights reserved.

Electrical dyssynchrony Abnormal ventricular depolarization, causing increased QRSd generates early and delayed ventricular contraction QRSd directly associated with EF BBB present in 20% of HF patients and 35% of patients with severely impaired EF BBB is an independent predictor of mortality especially QRSd > 120 ms

Mechanical dyssynchrony Intraventricular- refers to delayed activation of one LV region to another Interventricular- refers to delayed activation of LV relative to RV CRT aims to correct both

Achieving Cardiac Resynchronization Goal: Atrial synchronous biventricular pacing Transvenous approach for left ventricular lead via coronary sinus Back-up epicardial approach Right Atrial Lead Right Ventricular Lead Left Ventricular Lead From Dr. A. Goldman’s CRT Talk 2007

Cumulative Enrollment in Cardiac Resynchronization Randomized Trials Results Presented Cumulative Patients PATH CHF MUSTIC SR MUSTIC AF MIRACLE CONTAK CD MIRACLE ICD PATH CHF II COMPANION MIRACLE ICD II CARE HF

CRT benefits Reduced mitral regurgitation Increased 6-minute hall walk distance Improved NYHA functional class ranking Increased peak VO2 and treadmill exercise time Reduced QRS duration Reversal of maladaptive remodeling Fewer days in hospital over 6 months Improved clinical composite response Reduced morbidity and mortality

Improvement with CRT - MR

Regional Wall Motion With CRT: Improved LVEF Septum Lateral Pacing Off Pacing On Regional Fractional Area Change Seconds0.40 Seconds0.40 Adapted from Kass DA. Rev Cardiovasc Med. 2003;4(suppl 2):S3-S13. Adapted from Kawaguchi M, et al. J Am Coll Cardiol. 2002;39:

CRT Promotes Reverse Remodeling in Class II CHF  Control (n=85)  CRT (n=69) Abraham et al., Circulation 2004; 110: P=0.04P=0.01P=0.02

CRT Improves Quality of Life and NYHA Functional Class * P < 0.05 Abraham et al., 2003

CRT Improves Exercise Capacity * P < 0.05 Abraham et al., 2003

Progressive Heart Failure Mortality 51% Relative Reduction with CRT Favors CRTFavors No CRT CONTAK CD (n=490) MIRACLE ICD (n=554) MIRACLE (n=532) MUSTIC (n=58) Overall (n=1634) Bradley DJ, et al. JAMA 2003;289: Overall odds ratio (95% CI) of 0.49 ( )

Summary of Major Trials Significant clinical benefit of CRT in patients with class III-IV HF, low EF, and QRS > 120 Improvement in symptoms Improvement in objective standards of HF Meta-analysis 29% decrease in HF hospitalization (13% vs. 17.4%) 51% decrease in deaths from HF (1.7% vs. 3.5%) Trend toward decrease in overall mortality (4.9% vs 6.3%) BUT: >30% non-responders consistent through most trials Bradley et al. JAMA 2003;289:730

How to best predict who will respond to CRT? ?Use of Echo/ imaging parameters

Intraventricular Dyssynchrony M-Mode Echo Tissue Velocity Strain Imaging Three Dimensional Echo

M-Mode Septal to posterior wall delay Measures time between maximal displacement of septum and posterior wall (SPWMD) ≥ 130 ms considered significant Easy to perform No specific equipment needed

Copyright ©2008 American Heart Association Anderson, L. J. et al. Circulation 2008;117: M-mode echocardiography with color-coded tissue velocity. a, Timing of ventricular septal (VS) wall motion is difficult to define because of its severe hypokinesis and the lack of distinct peaks. b, Color coding of tissue velocity helps to identify the exact wall motion timing as transition point of blue to red color for septal wall (arrows) and red to blue color for posterior wall (arrowheads) (right)

M-Mode- SPWMD Disadvantages Can only be quantified in regions perpendicular to U/S beam Only feasible in half of patients studied In several reports, septal-posterior wall delay didn’t predict outcome after CRT Only assesses motion of septal and posterior walls

Tissue Velocity Measurement of either longitudinal tissue velocity or deformation (strain) - Opposing wall peak delay of > ms Yu index: global 12 segment Asynchrony Index ≥ 33 ms 3 High temporal resolution Color-coded TDI- allows simultaneous processing of multiple samples from the same image Susceptible to translational motion or tethering effect Bax et al, Am J Card 2003 Bax et al, Am J Card 2004

Copyright ©2008 American Heart Association Anderson, L. J. et al. Circulation 2008;117: Tissue velocity waveforms in a normal subject from 4-chamber (left), apical long-axis (middle), and 2-chamber views (right )

Copyright ©2008 American Heart Association Anderson, L. J. et al. Circulation 2008;117: Color-coded tissue velocity recordings from 12 LV segments before (a) and after (b) CRT in 65-year-old patient with nonischemic cardiomyopathy whose LVEF improved by 17% at 6 months after CRT Before CRT After CRT Apical 4 ChLong axis2 Chamber

Tissue Velocity- Disadvantages Susceptible to translational motion or tethering effect Color coding can vary with time window setting Requires specific equipment

Strain Imaging TDI-derived and Speckle tracking Abnormal strain pattern- premature early systolic shortening of septum accompanied by lateral prestretch and followed by postsystolic lateral wall shortening Less affected by tethering / translational motion

Copyright ©2008 American Heart Association Anderson, L. J. et al. Circulation 2008;117: Radial strain curves from short-axis view of speckle tracking Echocardiography: Significant timing difference was found among time to peak radial strain before CRT (a), and it was reduced after CRT (b).

Strain imaging Dependent on image quality; not feasible in all patients Mixed results with respects to predicting success after CRT

3-D Echo Only one image allows entire assessment Short-term improvements in 3-D dyssynchrony index noted after CRT

Three Dimensional Echocardiography

3-D Echo No study to date shows 3D Echo predicts response to CRT Highly dependent on image quality Incomplete inclusion of the apex Can’t perform in a-fib or rhythm with several ectopic beats

Interventricular Dyssynchrony Difference in preejection period between PW doppler in Ao and PA - Correlates with QRSd - Exceeds 40s in patients with QRDs>150 ms - Shown to be predictive of response post-CRT in SCART and CARE-HF trials TV delay between RV and LV free wall not predictive of effect of CRT

Evidence for echo in predicting CRT outcomes Limited echo-CRT studies with hard endpoints Thus far, trials have enrolled 4000 patients based on ECG versus ~500 by echocardiogram PROSPECT Study- largest study

Copyright ©2008 American Heart Association Chung, E. S. et al. Circulation 2008;117: Enrollment and follow-up of patients in PROSPECT

PROSPECT patient population Mean age 68 years Male71% NYHA class III96% Mean LVEF23% Prior MI48% Beta-blockers85% Ace-I92%

Endpoints- Composite clinical score Worsened (died, hospitalized, worsened heart failure, demonstrated worsening in NYHA class at last observation carried forward, moderate or marked worsening of patient global assessment score at last observation carried forward, or permanently discontinued CRT because of or associated with worsening heart failure Improved (not worsened as defined above and demonstrated improvement in NYHA class at last observation carried forward or had moderate or marked improvement in patient global assessment score at last observation carried forward) Unchanged (the patient was neither improved nor worsened)

Copyright ©2008 American Heart Association Chung, E. S. et al. Circulation 2008;117: PROSPECT RESULTS: CCS and LVESV response rates

Area Under the Curve

PROSPECT Conclusions Echocardiographic measures of dyssynchrony aimed at improving patient selection criteria for CRT did not have a clinically relevant impact on improving response rates Echocardiographic parameters assessing dyssynchrony do not have enough predictive value to be recommended as selection criteria for CRT beyond current indications

Current ACC/AHA/NASPE 2005 Guideline Update Patients with LVEF 35%, sinus rhythm, and New York Heart Association functional class III or ambulatory class IV symptoms despite recommended optimal medical therapy and who have cardiac dyssynchrony, which is currently defined as a QRS duration >120 ms, should receive CRT unless contraindicated (Class: I, Level of Evidence: A).

Other roles for Echo in CRT Assess LVEF Assess pre- and post-valvular regurgitation Assess best location of lead placement

Future directions >30% non-responders consistent through most trials Studies should aim to characterize the non- responders